Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY900014 versus Humalog in children and adolescents with type 1 diabetes
2018-002371-18Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of insulin lispro and human insulin in diabetes mellitus type 1 (T1D) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Difference between LY900014 and Humalog in change from baseline to Week 26 in HbA1c. Started Mar 2019; status: completed.
02
Drugs
insulin lisprohuman insulin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2018-002371-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002371-18.